OS Therapies Inc (OSTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.9M
Cash & Equivalents
$4.6M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$75M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-31 | Phase1 Readout | — |
| 2026-07-31 | Phase1 Readout | — |
| 2026-08-01 | Phase1 Readout | — |
| 2026-08-01 | Phase3 Readout | — |
| 2026-08-01 | Phase2 Readout | — |
| 2026-08-30 | Phase2 Readout | — |
| 2026-08-31 | Phase2 Readout | — |
| 2026-08-31 | Phase2 Readout | — |
| 2026-09-01 | Phase1 Readout | — |
| 2026-09-01 | Phase1 Readout | — |
| 2026-09-15 | Phase2 Readout | — |
| 2026-09-30 | Phase2 Readout | — |
| 2026-09-30 | Phase3 Readout | — |
| 2026-10-01 | Phase3 Readout | — |
| 2026-10-30 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-11-30 | Phase2 Readout | — |
| 2026-11-30 | Phase1 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06140589 | Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer | OTHER | Recruiting | 200 |
| NCT06608823 | ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | OTHER | Recruiting | 1,016 |
| NCT06140719 | xPedite: A Study to Expedite DIPG and DMG Research | OTHER | Recruiting | 400 |
| NCT06397560 | PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial | OTHER | Recruiting | 28 |
| NCT06867484 | Breast Re-irradiation After Second Ipsilateral Lumpectomy | OTHER | Recruiting | 114 |
| NCT06225505 | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) | OTHER | Recruiting | 450 |
| NCT06455787 | J-Valve Transfemoral Pivotal Study | OTHER | Recruiting | 194 |
| NCT05052671 | ctDNA Assay in Patients With Resectable Pancreatic Cancer | OTHER | Recruiting | 50 |
| NCT07151118 | ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer | OTHER | Recruiting | 100 |
| NCT05342883 | GammaTile and Stupp in Newly Diagnosed GBM | PHASE4 | Active Not Recruiting | 61 |
| NCT07010523 | Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors | OTHER | Recruiting | 24 |
| NCT06606028 | Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma | OTHER | Recruiting | 250 |
| NCT07291180 | A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherap... | OTHER | Recruiting | 20 |
| NCT06533163 | Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-... | OTHER | Recruiting | 30 |
| NCT06011954 | A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection | OTHER | Recruiting | 202 |
| NCT06744296 | Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Ind... | OTHER | Recruiting | 75 |
| NCT04994717 | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older ... | PHASE3 | Active Not Recruiting | 303 |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cel... | PHASE3 | Recruiting | 695 |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | PHASE3 | Active Not Recruiting | 1,837 |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap... | PHASE3 | Recruiting | 614 |
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | PHASE3 | Recruiting | 641 |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic... | PHASE3 | Active Not Recruiting | 592 |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | PHASE3 | Active Not Recruiting | 575 |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small... | PHASE3 | Recruiting | 138 |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C... | PHASE3 | Recruiting | 680 |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, ... | PHASE3 | Recruiting | 3,680 |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Meta... | PHASE3 | Active Not Recruiting | 10 |
| NCT02997228 | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Ca... | PHASE3 | Active Not Recruiting | 120 |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Plat... | PHASE3 | Active Not Recruiting | 640 |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previous... | PHASE3 | Active Not Recruiting | 600 |
| NCT07005102 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With... | PHASE3 | Recruiting | 854 |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | PHASE3 | Recruiting | 135 |
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | PHASE3 | Recruiting | 180 |
| NCT06236438 | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With B... | PHASE3 | Recruiting | 840 |
| NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syn... | PHASE3 | Recruiting | 490 |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | PHASE3 | Recruiting | 680 |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | PHASE3 | Recruiting | 286 |
| NCT04784715 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Met... | PHASE3 | Active Not Recruiting | 1,157 |
| NCT06238843 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously... | PHASE3 | Active Not Recruiting | 464 |
| NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult ... | PHASE3 | Recruiting | 800 |
| NCT06745024 | Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PR... | PHASE3 | Active Not Recruiting | 280 |
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | PHASE3 | Active Not Recruiting | 125 |
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With m... | PHASE3 | Active Not Recruiting | 1,052 |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | PHASE3 | Recruiting | 486 |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Ace... | PHASE3 | Active Not Recruiting | 496 |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (R... | PHASE3 | Recruiting | 413 |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible f... | PHASE3 | Active Not Recruiting | 302 |
| NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive ... | PHASE3 | Recruiting | 540 |
| NCT07195591 | Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care | PHASE3 | Recruiting | 766 |
| NCT06647862 | IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) | PHASE3 | Recruiting | 170 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-02 | 8-K | OS Therapies Inc (OSTX) (CIK 0001795091) - PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON JULY 2, 2026 | EDGAR |